| Year |
Citation |
Score |
| 2023 |
Gandhi S, Opyrchal M, Grimm MJ, Slomba RT, Kokolus KM, Witkiewicz A, Attwood K, Groman A, Williams L, Tarquini ML, Wallace PK, Soh KT, Minderman H, Maguire O, O'Connor TL, ... ... Kalinski P, et al. Systemic infusion of TLR3-ligand and IFN-α in patients with breast cancer reprograms local tumor microenvironments for selective CTL influx. Journal For Immunotherapy of Cancer. 11. PMID 37963636 DOI: 10.1136/jitc-2023-007381 |
0.357 |
|
| 2023 |
Dong B, Obermajer N, Tsuji T, Matsuzaki J, Bonura C, Withers H, Long M, Chavel C, Olejniczak SH, Minderman H, Edwards RP, Storkus WJ, Romero P, Kalinski P. NK Receptors Replace CD28 As the Dominant Source of Signal 2 for Cognate Recognition of Cancer Cells by TAA-specific Effector CD8 T Cells. Research Square. PMID 37886562 DOI: 10.21203/rs.3.rs-3399211/v1 |
0.463 |
|
| 2022 |
Suarez Mora A, Strange M, Fang Y, Uygun I, Zhang L, Tseng GC, Kalinski P, Edwards RP, Vlad AM. Longitudinal Modulation of Loco-Regional Immunity in Ovarian Cancer Patients Receiving Intraperitoneal Chemotherapy. Cancers. 14. PMID 36428740 DOI: 10.3390/cancers14225647 |
0.321 |
|
| 2022 |
Alam A, Levanduski E, Denz P, Villavicencio HS, Bhatta M, Alhorebi L, Zhang Y, Gomez EC, Morreale B, Senchanthisai S, Li J, Turowski SG, Sexton S, Sait SJ, Singh PK, ... ... Kalinski P, et al. Fungal mycobiome drives IL-33 secretion and type 2 immunity in pancreatic cancer. Cancer Cell. PMID 35120601 DOI: 10.1016/j.ccell.2022.01.003 |
0.36 |
|
| 2022 |
Orr B, Mahdi H, Fang Y, Strange M, Uygun I, Rana M, Zhang L, Suarez Mora A, Pusateri A, Elishaev E, Kang C, Tseng G, Gooding W, Edwards RP, Kalinski P, et al. Phase I trial combining chemokine-targeting with loco-regional chemo-immunotherapy for recurrent, platinum-sensitive ovarian cancer shows induction of CXCR3 ligands and markers of type 1 immunity. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 35046055 DOI: 10.1158/1078-0432.CCR-21-3659 |
0.323 |
|
| 2021 |
Basu A, Albert GK, Awshah S, Datta J, Kodumudi KN, Gallen C, Beyer A, Smalley KSM, Rodriguez PC, Dukett DR, Forsyth PA, Soyano A, Koski GK, Lima Barros Costa R, Han H, ... ... Kalinski P, et al. Identification of immunogenic MHC class II human HER3 peptides that mediate anti-HER3 CD4+ Th1 responses and potential use as a cancer vaccine. Cancer Immunology Research. PMID 34785506 DOI: 10.1158/2326-6066.CIR-21-0454 |
0.326 |
|
| 2021 |
Oshi M, Kawaguchi T, Yan L, Peng X, Qi Q, Tian W, Schulze A, McDonald KA, Narayanan S, Young J, Liu S, Morris LG, Chan TA, Kalinski P, Matsuyama R, et al. Immune cytolytic activity is associated with reduced intra-tumoral genetic heterogeneity and with better clinical outcomes in triple negative breast cancer. American Journal of Cancer Research. 11: 3628-3644. PMID 34354864 |
0.308 |
|
| 2021 |
Ibrahim OM, Basse PH, Jiang W, Guru K, Chatta G, Kalinski P. NFκB-Activated COX2/PGE/EP4 Axis Controls the Magnitude and Selectivity of BCG-Induced Inflammation in Human Bladder Cancer Tissues. Cancers. 13. PMID 33809455 DOI: 10.3390/cancers13061323 |
0.312 |
|
| 2020 |
Oshi M, Newman S, Tokumaru Y, Yan L, Matsuyama R, Kalinski P, Endo I, Takabe K. Plasmacytoid Dendritic Cell (pDC) Infiltration Correlate with Tumor Infiltrating Lymphocytes, Cancer Immunity, and Better Survival in Triple Negative Breast Cancer (TNBC) More Strongly than Conventional Dendritic Cell (cDC). Cancers. 12. PMID 33198125 DOI: 10.3390/cancers12113342 |
0.425 |
|
| 2020 |
Singh MV, Suwunnakorn S, Simpson SR, Weber EA, Singh VB, Kalinski P, Maggirwar SB. Monocytes complexed to platelets differentiate into functionally deficient dendritic cells. Journal of Leukocyte Biology. PMID 32663904 DOI: 10.1002/Jlb.3A0620-460Rr |
0.483 |
|
| 2020 |
Sonmez UM, Wood A, Justus K, Jiang W, Syed-Picard F, LeDuc PR, Kalinski P, Davidson LA. Chemotactic Responses of Jurkat Cells in Microfluidic Flow-Free Gradient Chambers. Micromachines. 11. PMID 32260431 DOI: 10.3390/Mi11040384 |
0.773 |
|
| 2020 |
Kokolus KM, Obermajer N, Kalinski P. Quantitative evaluation of tumor-specific T cells in tumors and lymphoid tissues. Methods in Enzymology. 635: 149-166. PMID 32122543 DOI: 10.1016/Bs.Mie.2019.05.041 |
0.485 |
|
| 2020 |
Katsuta E, Yan L, Opyrchal M, Kalinski P, Takabe K. Functional hotness score based on three genes predicts long-term survival of triple-negative breast cancer independent from tumor mutational burden. Journal of Clinical Oncology. 38: e12583-e12583. DOI: 10.1200/Jco.2020.38.15_Suppl.E12583 |
0.372 |
|
| 2020 |
Boland PM, Muhitch J, Abrams SI, Maguire O, Minderman H, Bajor DL, Saltzman JN, Wang K, Hutson A, Mukherjee S, Iyer RV, Kalinski P, Fountzilas C. Initial correlative studies from a trial of cetuximab and pembrolizumab in metastatic colorectal cancer (mCRC). Journal of Clinical Oncology. 38: 4062-4062. DOI: 10.1200/Jco.2020.38.15_Suppl.4062 |
0.407 |
|
| 2020 |
Katsuta E, Yan L, Opyrchal M, Kalinski P, Takabe K. Abstract P3-07-07: Functional hotness score of cytotoxic T-lymphocytes infiltration to predicts outcome of triple-negative breast cancer patients Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P3-07-07 |
0.392 |
|
| 2020 |
Dong B, Pabla S, Giamo V, Jiang W, Taniguchi K, Glenn ST, Shirai M, Kalinski P. Abstract 968: Distinct pathways of DC-induced CD8+T cell differentiation revealed by single-cell mRNA sequencing analysis Immunology. 80: 968-968. DOI: 10.1158/1538-7445.Am2020-968 |
0.531 |
|
| 2020 |
Katsuta E, Yan L, Opyrchal M, Kalinski P, Takabe K. Abstract 6616: Functional hotness score generated by representative functional cytotoxic T-lymphocytes predicts long-term survival of triple-negative breast cancer independently to the tumor mutational burden Immunology. DOI: 10.1158/1538-7445.Am2020-6616 |
0.325 |
|
| 2019 |
Yang Y, Zhang Y, Wang J, Krolewski J, Levine EG, Mohler J, Chatta GS, Kalinski P. Differences in immune tumor microenvironment between primary and metastatic castration-resistant prostate cancer. Journal of Clinical Oncology. 37: 58-58. DOI: 10.1200/Jco.2019.37.8_Suppl.58 |
0.454 |
|
| 2019 |
Yang Y, George S, Levine EG, Schwaab T, Muhitch J, Li Q, Attwood K, Groman A, Abrams SI, Kalinski P, Singh AK, Guru K, Chatta GS. Interim analysis of a pilot study: Impact of high-dose, single fraction radiation on immunogenicity of sipuleucel-T in metastatic castration resistant prostate cancer patients. Journal of Clinical Oncology. 37: e16538-e16538. DOI: 10.1200/Jco.2019.37.15_Suppl.E16538 |
0.323 |
|
| 2019 |
Fountzilas C, Wilkinson GA, Eng KH, Fields P, Arora SP, Kalinski P, Raber P, Nuovo G, Coffey MC, Mahalingam D. Prediction of response to pelareorep plus pembrolizumab in pancreatic ductal adenocarcinoma (PDAC). Journal of Clinical Oncology. 37: e15726-e15726. DOI: 10.1200/Jco.2019.37.15_Suppl.E15726 |
0.376 |
|
| 2018 |
Theodoraki MN, Yerneni S, Sarkar SN, Orr B, Muthuswamy R, Voyten J, Modugno F, Jiang W, Grimm M, Basse PH, Bartlett DL, Edwards R, Kalinski P. Helicase-driven activation of NFκB-COX2 mediates the immunosuppressive component of dsRNA-driven inflammation in the human tumor microenvironment. Cancer Research. PMID 29853604 DOI: 10.1158/0008-5472.Can-17-3985 |
0.468 |
|
| 2018 |
Obermajer N, Urban J, Wieckowski E, Muthuswamy R, Ravindranathan R, Bartlett DL, Kalinski P. Promoting the accumulation of tumor-specific T cells in tumor tissues by dendritic cell vaccines and chemokine-modulating agents. Nature Protocols. 13: 335-357. PMID 29345636 DOI: 10.1038/Nprot.2017.130 |
0.462 |
|
| 2018 |
Yang Y, Attwood K, Versaggi C, Omilian A, Bshara W, Xu B, Kauffman E, Mohler J, Guru K, Li Q, George S, Basse P, Morrison C, Papanicolau-Sengos A, Kalinski P, et al. Association of high CD8+ tumor infiltrating lymphocytes at prostatectomy with improved survival of prostate cancer patients. Journal of Clinical Oncology. 36: 5068-5068. DOI: 10.1200/Jco.2018.36.15_Suppl.5068 |
0.364 |
|
| 2018 |
Sonmez UM, LeDuc PR, Kalinski P, Davidson LA. Chemotaxis of Immune Cells in Microfluidic Flow-Free Concentration Gradient Generator Biophysical Journal. 114: 217a. DOI: 10.1016/J.Bpj.2017.11.1211 |
0.751 |
|
| 2017 |
Kalinski P, Talmadge JE. Tumor Immuno-Environment in Cancer Progression and Therapy. Advances in Experimental Medicine and Biology. 1036: 1-18. PMID 29275461 DOI: 10.1007/978-3-319-67577-0_1 |
0.356 |
|
| 2017 |
Rodríguez-Ubreva J, Català-Moll F, Obermajer N, Álvarez-Errico D, Ramirez RN, Company C, Vento-Tormo R, Moreno-Bueno G, Edwards RP, Mortazavi A, Kalinski P, Ballestar E. Prostaglandin E2 Leads to the Acquisition of DNMT3A-Dependent Tolerogenic Functions in Human Myeloid-Derived Suppressor Cells. Cell Reports. 21: 154-167. PMID 28978469 DOI: 10.1016/J.Celrep.2017.09.018 |
0.48 |
|
| 2017 |
Budiu RA, Vlad AM, Nazario L, Bathula C, Cooper KL, Edmed J, Thaker PH, Urban J, Kalinski P, Lee AV, Elishaev EL, Conrads TP, Flint MS. Restraint and Social Isolation Stressors Differentially Regulate Adaptive Immunity and Tumor Angiogenesis in a Breast Cancer Mouse Model. Cancer and Clinical Oncology. 6: 12-24. PMID 28603578 DOI: 10.5539/Cco.V6N1P12 |
0.395 |
|
| 2017 |
Guo ZS, Liu Z, Kowalsky S, Feist M, Kalinski P, Lu B, Storkus WJ, Bartlett DL. Oncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future Perspectives. Frontiers in Immunology. 8: 555. PMID 28555136 DOI: 10.3389/Fimmu.2017.00555 |
0.53 |
|
| 2017 |
Liu Z, Ravindranathan R, Kalinski P, Guo ZS, Bartlett DL. Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy. Nature Communications. 8: 14754. PMID 28345650 DOI: 10.1038/Ncomms14754 |
0.372 |
|
| 2017 |
Muthuswamy R, Okada NJ, Jenkins FJ, McGuire K, McAuliffe PF, Zeh HJ, Bartlett DL, Wallace C, Watkins S, Henning JD, Bovbjerg DH, Kalinski P. Epinephrine Promotes COX-2-dependent Immune Suppression in Myeloid Cells and Cancer Tissues. Brain, Behavior, and Immunity. PMID 28212885 DOI: 10.1016/J.Bbi.2017.02.008 |
0.468 |
|
| 2016 |
Muthuswamy R, Corman JM, Dahl K, Chatta GS, Kalinski P. Functional reprogramming of human prostate cancer to promote local attraction of effector CD8(+) T cells. The Prostate. PMID 27199259 DOI: 10.1002/Pros.23194 |
0.431 |
|
| 2016 |
Liu Z, Ravindranathan R, Li J, Kalinski P, Guo ZS, Bartlett DL. CXCL11-Armed oncolytic poxvirus elicits potent antitumor immunity and shows enhanced therapeutic efficacy. Oncoimmunology. 5: e1091554. PMID 27141352 DOI: 10.1080/2162402X.2015.1091554 |
0.547 |
|
| 2016 |
Radomski M, Zeh HJ, Edington HD, Pingpank JF, Butterfield LH, Whiteside TL, Wieckowski E, Bartlett DL, Kalinski P. Prolonged intralymphatic delivery of dendritic cells through implantable lymphatic ports in patients with advanced cancer. Journal For Immunotherapy of Cancer. 4: 24. PMID 27096100 DOI: 10.1186/S40425-016-0128-Y |
0.359 |
|
| 2016 |
Francis L, Guo ZS, Liu Z, Ravindranathan R, Urban JA, Sathaiah M, Magge D, Kalinski P, Bartlett DL. Modulation of chemokines in the tumor microenvironment enhances oncolytic virotherapy for colorectal cancer. Oncotarget. PMID 26956047 DOI: 10.18632/Oncotarget.7907 |
0.521 |
|
| 2016 |
Wong JL, Obermajer N, Odunsi K, Edwards RP, Kalinski P. Synergistic COX2 induction by IFNγ and TNFα self-limits type-1 immunity in the human tumor microenvironment. Cancer Immunology Research. PMID 26817996 DOI: 10.1158/2326-6066.Cir-15-0157 |
0.488 |
|
| 2015 |
Liu J, Li F, Ping Y, Wang L, Chen X, Wang D, Cao L, Zhao S, Li B, Kalinski P, Thorne SH, Zhang B, Zhang Y. Local production of the chemokines CCL5 and CXCL10 attracts CD8+ T lymphocytes into esophageal squamous cell carcinoma. Oncotarget. PMID 26317795 DOI: 10.18632/Oncotarget.4617 |
0.43 |
|
| 2015 |
Liu JY, Li F, Wang LP, Chen XF, Wang D, Cao L, Ping Y, Zhao S, Li B, Thorne SH, Zhang B, Kalinski P, Zhang Y. CTL- vs Treg lymphocyte-attracting chemokines, CCL4 and CCL20, are strong reciprocal predictive markers for survival of patients with oesophageal squamous cell carcinoma. British Journal of Cancer. PMID 26284335 DOI: 10.1038/Bjc.2015.290 |
0.419 |
|
| 2015 |
Apetoh L, Smyth MJ, Drake CG, Abastado JP, Apte RN, Ayyoub M, Blay JY, Bonneville M, Butterfield LH, Caignard A, Castelli C, Cavallo F, Celis E, Chen L, Colombo MP, ... ... Kalinski P, et al. Consensus nomenclature for CD8(+) T cell phenotypes in cancer. Oncoimmunology. 4: e998538. PMID 26137416 DOI: 10.1080/2162402X.2014.998538 |
0.497 |
|
| 2015 |
Low CA, Kalinski P, Bovbjerg DH. Neurocognitive Impairment as One Facet of Cancer-Related Sickness Behavior Symptoms. Journal of the National Cancer Institute. 107. PMID 26101332 DOI: 10.1093/Jnci/Djv176 |
0.329 |
|
| 2015 |
Muthuswamy R, Wang L, Pitteroff J, Gingrich JR, Kalinski P. Combination of IFNα and poly-I:C reprograms bladder cancer microenvironment for enhanced CTL attraction. Journal For Immunotherapy of Cancer. 3: 6. PMID 25806105 DOI: 10.1186/S40425-015-0050-8 |
0.456 |
|
| 2015 |
Zaccard CR, Watkins SC, Kalinski P, Fecek RJ, Yates AL, Salter RD, Ayyavoo V, Rinaldo CR, Mailliard RB. CD40L induces functional tunneling nanotube networks exclusively in dendritic cells programmed by mediators of type 1 immunity. Journal of Immunology (Baltimore, Md. : 1950). 194: 1047-56. PMID 25548234 DOI: 10.4049/Jimmunol.1401832 |
0.541 |
|
| 2015 |
Zeh HJ, Downs-Canner S, McCart JA, Guo ZS, Rao UN, Ramalingam L, Thorne SH, Jones HL, Kalinski P, Wieckowski E, O'Malley ME, Daneshmand M, Hu K, Bell JC, Hwang TH, et al. First-in-man study of western reserve strain oncolytic vaccinia virus: safety, systemic spread, and antitumor activity. Molecular Therapy : the Journal of the American Society of Gene Therapy. 23: 202-14. PMID 25292189 DOI: 10.1038/Mt.2014.194 |
0.323 |
|
| 2015 |
Downs-Canner S, Ravindranathan R, Edwards RP, Kalinski P, Odunsi K, Bartlett DL, Obermajer N. Ex-Th17 Foxp3+ T cells - a novel subset of Foxp3+ T cells induced in cancer Journal For Immunotherapy of Cancer. 3: P273. DOI: 10.1186/2051-1426-3-S2-P273 |
0.549 |
|
| 2015 |
Hansen M, Wieckowski E, Svane IM, Edwards RP, Kalinski P. Selective costimulation by IL-15R/IL-15, but not IL-2R/IL-2, allows the induction of high numbers of tumor-specific CD8+ T cells by human dendritic cells matured in conditions of acute inflammation Journal For Immunotherapy of Cancer. 3. DOI: 10.1186/2051-1426-3-S2-P223 |
0.486 |
|
| 2014 |
Nguyen T, Urban J, Kalinski P. Therapeutic cancer vaccines and combination immunotherapies involving vaccination. Immunotargets and Therapy. 3: 135-50. PMID 27471705 DOI: 10.2147/ITT.S40264 |
0.381 |
|
| 2014 |
Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqué A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, Apte RN, Aranda F, Ayyoub M, Beckhove P, Blay JY, ... ... Kalinski P, et al. Classification of current anticancer immunotherapies. Oncotarget. 5: 12472-508. PMID 25537519 DOI: 10.18632/Oncotarget.2998 |
0.398 |
|
| 2014 |
Wong JL, Obermajer N, Muthuswamy R, Edwards RP, Odunsi K, Bartlett DL, Kalinski P. Activation of the COX2-PGE2 axis by immune effector cells results in the self-limiting nature of type-1 immunity in cancer tissues Journal For Immunotherapy of Cancer. 2. DOI: 10.1186/2051-1426-2-S3-P239 |
0.506 |
|
| 2014 |
Smith-Cohn M, Kohanbash G, Muthuswamy R, Ohkuri T, Kosaka A, Amankulor N, Engh J, Potter D, Kalinski P, Okada H. IT-33 * USE OF IFN-ALPHA AND POLY-ICLC AS CHEMOKINE MODULATORS FOR IMMUNOTHERAPY IN GLIOMAS Neuro-Oncology. 16: v117-v117. DOI: 10.1093/Neuonc/Nou258.31 |
0.457 |
|
| 2013 |
Wong JL, Muthuswamy R, Bartlett DL, Kalinski P. IL-18-based combinatorial adjuvants promote the intranodal production of CCL19 by NK cells and dendritic cells of cancer patients. Oncoimmunology. 2: e26245. PMID 24228233 DOI: 10.4161/Onci.26245 |
0.583 |
|
| 2013 |
Obermajer N, Wong JL, Edwards RP, Chen K, Scott M, Khader S, Kolls JK, Odunsi K, Billiar TR, Kalinski P. Induction and stability of human Th17 cells require endogenous NOS2 and cGMP-dependent NO signaling. The Journal of Experimental Medicine. 210: 1433-445. PMID 23797095 DOI: 10.1084/Jem.20121277 |
0.479 |
|
| 2013 |
Wong JL, Berk E, Edwards RP, Kalinski P. IL-18-primed helper NK cells collaborate with dendritic cells to promote recruitment of effector CD8+ T cells to the tumor microenvironment. Cancer Research. 73: 4653-62. PMID 23761327 DOI: 10.1158/0008-5472.Can-12-4366 |
0.804 |
|
| 2013 |
Kalinski P, Muthuswamy R, Urban J. Dendritic cells in cancer immunotherapy: vaccines and combination immunotherapies. Expert Review of Vaccines. 12: 285-95. PMID 23496668 DOI: 10.1586/Erv.13.22 |
0.555 |
|
| 2013 |
Vernon PJ, Loux TJ, Schapiro NE, Kang R, Muthuswamy R, Kalinski P, Tang D, Lotze MT, Zeh HJ. The receptor for advanced glycation end products promotes pancreatic carcinogenesis and accumulation of myeloid-derived suppressor cells. Journal of Immunology (Baltimore, Md. : 1950). 190: 1372-9. PMID 23269246 DOI: 10.4049/Jimmunol.1201151 |
0.403 |
|
| 2013 |
Budiu RA, Elishaev E, Brozick J, Lee M, Edwards RP, Kalinski P, Vlad AM. Immunobiology of human mucin 1 in a preclinical ovarian tumor model. Oncogene. 32: 3664-75. PMID 22964632 DOI: 10.1038/Onc.2012.397 |
0.464 |
|
| 2013 |
Muthuswamy R, Jenkins F, Bovbjerg D, Kalinski P. Synergistic induction of cancer-related immunosuppression by β2-adrenergic stress mediators and P38MAPK inflammatory pathway Journal For Immunotherapy of Cancer. 1. DOI: 10.1186/2051-1426-1-S1-P191 |
0.337 |
|
| 2013 |
Obermajer N, Wong JL, Edwards RP, Chen K, Scott M, Khader S, Kolls JK, Odunsi K, Billiar TR, Kalinski P. Development and stability of Th17 cells in ovarian cancer requires nitric oxide and endogenous NOS2 activity in cancer-associated CD4+ T cells Journal For Immunotherapy of Cancer. 1. DOI: 10.1186/2051-1426-1-S1-P146 |
0.49 |
|
| 2013 |
Wong JL, Muthuswamy R, Bartlett DL, Kalinski P. IL-18-based combinatorial adjuvants promote the NK-DC-mediated production of the CCR7 ligand CCL19 in lymph nodes from cancer patients Journal For Immunotherapy of Cancer. 1. DOI: 10.1186/2051-1426-1-S1-O21 |
0.582 |
|
| 2013 |
Stroncek DF, Melief CJ, Castiello L, Cesano A, Cheever MA, Civini S, Comin-Anduix B, Gajewski TF, Greenberg PD, Kalinski P, Kaufman HL, Kershaw MH, Khleif SN, Marincola F, Merritt W, et al. Highlights of the society for immunotherapy of cancer (SITC) 27th annual meeting Journal For Immunotherapy of Cancer. 1. DOI: 10.1186/2051-1426-1-4 |
0.478 |
|
| 2013 |
Helfer BM, Balducci A, Urban J, Butterfield L, Ahrens E, Kalinski P, Wesa A. Abstract B44: Enabling in vivo visualization of cellular therapies in the clinic: Maturation of αDC1 data sets. Cancer Research. 73. DOI: 10.1158/1538-7445.Tumimm2012-B44 |
0.43 |
|
| 2012 |
Obermajer N, Kalinski P. Generation of myeloid-derived suppressor cells using prostaglandin E2. Transplantation Research. 1: 15. PMID 23369567 DOI: 10.1186/2047-1440-1-15 |
0.492 |
|
| 2012 |
Li J, O'Malley M, Sampath P, Kalinski P, Bartlett DL, Thorne SH. Expression of CCL19 from oncolytic vaccinia enhances immunotherapeutic potential while maintaining oncolytic activity. Neoplasia (New York, N.Y.). 14: 1115-21. PMID 23308044 DOI: 10.1593/Neo.121272 |
0.43 |
|
| 2012 |
Berk E, Kalinski P. Lymphocyte-polarized DC1s: Effective inducers of tumor-specific CTLs. Oncoimmunology. 1: 1443-1444. PMID 23243623 DOI: 10.4161/Onci.21295 |
0.772 |
|
| 2012 |
Tarhini AA, Butterfield LH, Shuai Y, Gooding WE, Kalinski P, Kirkwood JM. Differing patterns of circulating regulatory T cells and myeloid-derived suppressor cells in metastatic melanoma patients receiving anti-CTLA4 antibody and interferon-α or TLR-9 agonist and GM-CSF with peptide vaccination. Journal of Immunotherapy (Hagerstown, Md. : 1997). 35: 702-10. PMID 23090079 DOI: 10.1097/Cji.0B013E318272569B |
0.456 |
|
| 2012 |
Obermajer N, Wong JL, Edwards RP, Odunsi K, Moysich K, Kalinski P. PGE(2)-driven induction and maintenance of cancer-associated myeloid-derived suppressor cells. Immunological Investigations. 41: 635-57. PMID 23017139 DOI: 10.3109/08820139.2012.695417 |
0.48 |
|
| 2012 |
Obermajer N, Kalinski P. Key role of the positive feedback between PGE(2) and COX2 in the biology of myeloid-derived suppressor cells. Oncoimmunology. 1: 762-764. PMID 22934275 DOI: 10.4161/Onci.19681 |
0.389 |
|
| 2012 |
Muthuswamy R, Berk E, Junecko BF, Zeh HJ, Zureikat AH, Normolle D, Luong TM, Reinhart TA, Bartlett DL, Kalinski P. NF-κB hyperactivation in tumor tissues allows tumor-selective reprogramming of the chemokine microenvironment to enhance the recruitment of cytolytic T effector cells. Cancer Research. 72: 3735-43. PMID 22593190 DOI: 10.1158/0008-5472.CAN-11-4136 |
0.744 |
|
| 2012 |
Kirkwood JM, Butterfield LH, Tarhini AA, Zarour H, Kalinski P, Ferrone S. Immunotherapy of cancer in 2012. Ca: a Cancer Journal For Clinicians. 62: 309-35. PMID 22576456 DOI: 10.3322/Caac.20132 |
0.41 |
|
| 2012 |
Berk E, Muthuswamy R, Kalinski P. Lymphocyte-polarized dendritic cells are highly effective in inducing tumor-specific CTLs. Vaccine. 30: 6216-24. PMID 22561311 DOI: 10.1016/J.Vaccine.2012.04.077 |
0.794 |
|
| 2012 |
Qian F, Liao J, Villella J, Edwards R, Kalinski P, Lele S, Shrikant P, Odunsi K. Effects of 1-methyltryptophan stereoisomers on IDO2 enzyme activity and IDO2-mediated arrest of human T cell proliferation. Cancer Immunology, Immunotherapy : Cii. 61: 2013-20. PMID 22527253 DOI: 10.1007/S00262-012-1265-X |
0.456 |
|
| 2012 |
Kono M, Nakamura Y, Suda T, Uchijima M, Tsujimura K, Nagata T, Giermasz AS, Kalinski P, Nakamura H, Chida K. Enhancement of protective immunity against intracellular bacteria using type-1 polarized dendritic cell (DC) vaccine. Vaccine. 30: 2633-9. PMID 22365841 DOI: 10.1016/J.Vaccine.2012.02.026 |
0.522 |
|
| 2012 |
Kalinski P. Regulation of immune responses by prostaglandin E2. Journal of Immunology (Baltimore, Md. : 1950). 188: 21-8. PMID 22187483 DOI: 10.4049/Jimmunol.1101029 |
0.527 |
|
| 2012 |
Gopal R, Lin Y, Obermajer N, Slight S, Nuthalapati N, Ahmed M, Kalinski P, Khader SA. IL-23-dependent IL-17 drives Th1-cell responses following Mycobacterium bovis BCG vaccination. European Journal of Immunology. 42: 364-73. PMID 22101830 DOI: 10.1002/Eji.201141569 |
0.44 |
|
| 2012 |
Umemura N, Zhu J, Mburu YK, Forero A, Hsieh PN, Muthuswamy R, Kalinski P, Ferris RL, Sarkar SN. Defective NF-κB signaling in metastatic head and neck cancer cells leads to enhanced apoptosis by double-stranded RNA. Cancer Research. 72: 45-55. PMID 22058147 DOI: 10.1158/0008-5472.Can-11-1484 |
0.401 |
|
| 2011 |
Okada H, Kalinski P, Mintz AH, Engh JA, Butterfield LH, Hamilton RH, Potter DM, Salazar AM, Lieberman FS. Phase I/II vaccine study targeting novel HLA-A2-restricted CTL epitopes in combination with poly-ICLC in patients with recurrent malignant glioma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2506. PMID 28022390 DOI: 10.1200/Jco.2011.29.15_Suppl.2506 |
0.338 |
|
| 2011 |
Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, Atkins MB, Bartunkova J, Bergmann L, Berinstein N, Bonorino CC, Borden E, Bramson JL, Britten CM, Cao X, ... ... Kalinski P, et al. Defining the critical hurdles in cancer immunotherapy. Journal of Translational Medicine. 9: 214. PMID 22168571 DOI: 10.1186/1479-5876-9-214 |
0.335 |
|
| 2011 |
Obermajer N, Muthuswamy R, Odunsi K, Edwards RP, Kalinski P. PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. Cancer Research. 71: 7463-70. PMID 22025564 DOI: 10.1158/0008-5472.Can-11-2449 |
0.428 |
|
| 2011 |
Obermajer N, Muthuswamy R, Lesnock J, Edwards RP, Kalinski P. Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells. Blood. 118: 5498-505. PMID 21972293 DOI: 10.1182/Blood-2011-07-365825 |
0.533 |
|
| 2011 |
Kalinski P, Edington H, Zeh HJ, Okada H, Butterfield LH, Kirkwood JM, Bartlett DL. Dendritic cells in cancer immunotherapy: vaccines or autologous transplants? Immunologic Research. 50: 235-47. PMID 21717071 DOI: 10.1007/S12026-011-8224-Z |
0.499 |
|
| 2011 |
Balwit JM, Kalinski P, Sondak VK, Coulie PG, Jaffee EM, Gajewski TF, Marincola FM. Review of the 25th annual scientific meeting of the International Society for Biological Therapy of Cancer. Journal of Translational Medicine. 9: 60. PMID 21569425 DOI: 10.1186/1479-5876-9-60 |
0.422 |
|
| 2011 |
Kato M, Nakamura Y, Suda T, Ozawa Y, Inui N, Seo N, Nagata T, Koide Y, Kalinski P, Nakamura H, Chida K. Enhanced anti-tumor immunity by superantigen-pulsed dendritic cells. Cancer Immunology, Immunotherapy : Cii. 60: 1029-38. PMID 21519830 DOI: 10.1007/S00262-011-1015-5 |
0.578 |
|
| 2011 |
Yang DH, Kim MH, Lee YK, Hong CY, Lee HJ, Nguyen-Pham TN, Bae SY, Ahn JS, Kim YK, Chung IJ, Kim HJ, Kalinski P, Lee JJ. Successful cross-presentation of allogeneic myeloma cells by autologous alpha-type 1-polarized dendritic cells as an effective tumor antigen in myeloma patients with matched monoclonal immunoglobulins. Annals of Hematology. 90: 1419-26. PMID 21465188 DOI: 10.1007/S00277-011-1219-Y |
0.535 |
|
| 2011 |
Wong JL, Mailliard RB, Moschos SJ, Edington H, Lotze MT, Kirkwood JM, Kalinski P. Helper activity of natural killer cells during the dendritic cell-mediated induction of melanoma-specific cytotoxic T cells. Journal of Immunotherapy (Hagerstown, Md. : 1997). 34: 270-8. PMID 21389871 DOI: 10.1097/Cji.0B013E31820B370B |
0.58 |
|
| 2011 |
Li J, O'Malley M, Urban J, Sampath P, Guo ZS, Kalinski P, Thorne SH, Bartlett DL. Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer. Molecular Therapy : the Journal of the American Society of Gene Therapy. 19: 650-7. PMID 21266959 DOI: 10.1038/Mt.2010.312 |
0.457 |
|
| 2011 |
Zhao X, Bose A, Komita H, Taylor JL, Kawabe M, Chi N, Spokas L, Lowe DB, Goldbach C, Alber S, Watkins SC, Butterfield LH, Kalinski P, Kirkwood JM, Storkus WJ. Intratumoral IL-12 gene therapy results in the crosspriming of Tc1 cells reactive against tumor-associated stromal antigens. Molecular Therapy : the Journal of the American Society of Gene Therapy. 19: 805-14. PMID 21189473 DOI: 10.1038/Mt.2010.295 |
0.522 |
|
| 2011 |
Okada H, Kalinski P, Ueda R, Hoji A, Kohanbash G, Donegan TE, Mintz AH, Engh JA, Bartlett DL, Brown CK, Zeh H, Holtzman MP, Reinhart TA, Whiteside TL, Butterfield LH, et al. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 330-6. PMID 21149657 DOI: 10.1200/Jco.2010.30.7744 |
0.447 |
|
| 2011 |
Wieckowski E, Chatta GS, Mailliard RM, Gooding W, Palucka K, Banchereau J, Kalinski P. Type-1 polarized dendritic cells loaded with apoptotic prostate cancer cells are potent inducers of CD8(+) T cells against prostate cancer cells and defined prostate cancer-specific epitopes. The Prostate. 71: 125-33. PMID 20717900 DOI: 10.1002/Pros.21228 |
0.453 |
|
| 2011 |
Hong CY, Kalinski P, Kim H, Lee J. The Lymphoid Chemokine CCL21 Enhances the Migration- and CTL-Inducing Functions of Dendritic Cells Blood. 118: 1127-1127. DOI: 10.1182/Blood.V118.21.1127.1127 |
0.578 |
|
| 2011 |
Helfer BM, Balducci A, Kalinski P, Wesa A. Abstract LB-293: Perfluorocarbon labeling of human -type-1-polarized dendritic cells and conventional dendritic cells for in vivo trafficking by fluorine MRI Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Lb-293 |
0.397 |
|
| 2011 |
Obermajer N, Muthuswamy R, Lesnock J, Edwards RP, Kalinski P. Abstract LB-250: Establishment of a positive feedback between PGE2 and COX2 diverts DC differentiation into MDSCs and sustains their immunosuppressive functions in ovarian cancer Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Lb-250 |
0.462 |
|
| 2010 |
John E, Laskow TC, Buchser WJ, Pitt BR, Basse PH, Butterfield LH, Kalinski P, Lotze MT. Zinc in innate and adaptive tumor immunity. Journal of Translational Medicine. 8: 118. PMID 21087493 DOI: 10.1186/1479-5876-8-118 |
0.443 |
|
| 2010 |
Lesinski GB, Carson WE, Repasky EA, Wei WZ, Kalinski P, Lotze MT, June CH, Petros W, Muthusamy N, Olencki T. Meeting report: The 13th Annual Meeting of the Translational Research Cancer Centers Consortium (TrC3); Immune Suppression and the Tumor Microenvironment, Columbus, Ohio; March 1-2, 2010. Journal of Immunotherapy (Hagerstown, Md. : 1997). 33: 659-62. PMID 20664361 DOI: 10.1097/Cji.0B013E3181Eccbf7 |
0.319 |
|
| 2010 |
Zhu X, Fallert-Junecko BA, Fujita M, Ueda R, Kohanbash G, Kastenhuber ER, McDonald HA, Liu Y, Kalinski P, Reinhart TA, Salazar AM, Okada H. Poly-ICLC promotes the infiltration of effector T cells into intracranial gliomas via induction of CXCL10 in IFN-alpha and IFN-gamma dependent manners. Cancer Immunology, Immunotherapy : Cii. 59: 1401-9. PMID 20549206 DOI: 10.1007/S00262-010-0876-3 |
0.391 |
|
| 2010 |
Muthuswamy R, Mueller-Berghaus J, Haberkorn U, Reinhart TA, Schadendorf D, Kalinski P. PGE(2) transiently enhances DC expression of CCR7 but inhibits the ability of DCs to produce CCL19 and attract naive T cells. Blood. 116: 1454-9. PMID 20498301 DOI: 10.1016/J.Clim.2010.03.301 |
0.482 |
|
| 2010 |
Kalinski P, Okada H. Polarized dendritic cells as cancer vaccines: directing effector-type T cells to tumors. Seminars in Immunology. 22: 173-82. PMID 20409732 DOI: 10.1016/J.Smim.2010.03.002 |
0.596 |
|
| 2010 |
Yang DH, Kim MH, Hong CY, Lee YK, Jin CJ, Pham TN, Ahn JS, Bae WK, Kim YK, Chung IJ, Kim HJ, Kalinski P, Lee JJ. Alpha-type 1-polarized dendritic cells loaded with apoptotic allogeneic myeloma cell line induce strong CTL responses against autologous myeloma cells. Annals of Hematology. 89: 795-801. PMID 20238114 DOI: 10.1007/S00277-010-0931-3 |
0.498 |
|
| 2010 |
Helfer BM, Balducci A, Nelson AD, Janjic JM, Gil RR, Kalinski P, de Vries IJ, Ahrens ET, Mailliard RB. Functional assessment of human dendritic cells labeled for in vivo (19)F magnetic resonance imaging cell tracking. Cytotherapy. 12: 238-50. PMID 20053146 DOI: 10.3109/14653240903446902 |
0.422 |
|
| 2010 |
Watchmaker PB, Berk E, Muthuswamy R, Mailliard RB, Urban JA, Kirkwood JM, Kalinski P. Independent regulation of chemokine responsiveness and cytolytic function versus CD8+ T cell expansion by dendritic cells. Journal of Immunology (Baltimore, Md. : 1950). 184: 591-7. PMID 20018619 DOI: 10.4049/Jimmunol.0902062 |
0.807 |
|
| 2010 |
Kalinski P, Wieckowski E, Muthuswamy R, de Jong E. Generation of stable Th1/CTL-, Th2-, and Th17-inducing human dendritic cells. Methods in Molecular Biology (Clifton, N.J.). 595: 117-33. PMID 19941108 DOI: 10.1007/978-1-60761-421-0_7 |
0.561 |
|
| 2010 |
Okada H, Lieberman FS, Hoji A, Kalinski P, Mintz AH, Engh JA, Park DM, Bartlett DL, Zeh H, Whiteside TL, Butterfield LH, Hamilton RL, Salazar AM, Pollack IF. Abstract 4754: Type-1 dendritic cell vaccines in combination with poly-ICLC-association between positive tetramer response and 6-month progression-free survival in patients with recurrent malignant glioma Cancer Research. 70: 4754-4754. DOI: 10.1158/1538-7445.Am10-4754 |
0.451 |
|
| 2010 |
Muthuswamy R, Junecko B, Berk E, Luong TM, Schlesselmann J, Zeh H, Reinhart T, Bartlett D, Kalinski P. Tumor-selective Correction of the Chemokine Production in Colorectal Cancer to Enhance the Recruitment of Effector T Cells and Counteract Treg Infiltration Clinical Immunology. 135: S23. DOI: 10.1016/J.Clim.2010.03.074 |
0.464 |
|
| 2009 |
Lipscomb MW, Chen L, Taylor JL, Goldbach C, Watkins SC, Kalinski P, Butterfield LH, Wesa AK, Storkus WJ. Ectopic T-bet expression licenses dendritic cells for IL-12-independent priming of type 1 T cells in vitro. Journal of Immunology (Baltimore, Md. : 1950). 183: 7250-8. PMID 19915058 DOI: 10.4049/Jimmunol.0901477 |
0.544 |
|
| 2009 |
Sasaki K, Pardee AD, Qu Y, Zhao X, Ueda R, Kohanbash G, Bailey LM, Okada H, Muthuswamy R, Kalinski P, Basse PH, Falo LD, Storkus WJ. IL-4 suppresses very late antigen-4 expression which is required for therapeutic Th1 T-cell trafficking into tumors. Journal of Immunotherapy (Hagerstown, Md. : 1997). 32: 793-802. PMID 19752754 DOI: 10.1097/Cji.0B013E3181Acec1E |
0.511 |
|
| 2009 |
López-Albaitero A, Mailliard R, Hackman T, Andrade Filho PA, Wang X, Gooding W, Ferrone S, Kalinski P, Ferris RL. Maturation pathways of dendritic cells determine TAP1 and TAP2 levels and cross-presenting function. Journal of Immunotherapy (Hagerstown, Md. : 1997). 32: 465-73. PMID 19609238 DOI: 10.1097/Cji.0B013E3181A1C24E |
0.498 |
|
| 2009 |
Kalinski P. Dendritic cells in immunotherapy of established cancer: Roles of signals 1, 2, 3 and 4. Current Opinion in Investigational Drugs (London, England : 2000). 10: 526-35. PMID 19513941 |
0.442 |
|
| 2009 |
Kalinski P, Urban J, Narang R, Berk E, Wieckowski E, Muthuswamy R. Dendritic cell-based therapeutic cancer vaccines: What we have and what we need Future Oncology. 5: 379-390. PMID 19374544 DOI: 10.2217/Fon.09.6 |
0.774 |
|
| 2009 |
Fujita M, Zhu X, Ueda R, Sasaki K, Kohanbash G, Kastenhuber ER, McDonald HA, Gibson GA, Watkins SC, Muthuswamy R, Kalinski P, Okada H. Effective immunotherapy against murine gliomas using type 1 polarizing dendritic cells--significant roles of CXCL10. Cancer Research. 69: 1587-95. PMID 19190335 DOI: 10.1158/0008-5472.Can-08-2915 |
0.52 |
|
| 2009 |
Giermasz AS, Urban JA, Nakamura Y, Watchmaker P, Cumberland RL, Gooding W, Kalinski P. Type-1 polarized dendritic cells primed for high IL-12 production show enhanced activity as cancer vaccines. Cancer Immunology, Immunotherapy : Cii. 58: 1329-36. PMID 19156413 DOI: 10.1007/S00262-008-0648-5 |
0.543 |
|
| 2009 |
Sheridan BS, Cherpes TL, Urban J, Kalinski P, Hendricks RL. Reevaluating the CD8 T-cell response to herpes simplex virus type 1: involvement of CD8 T cells reactive to subdominant epitopes. Journal of Virology. 83: 2237-45. PMID 19073721 DOI: 10.1128/Jvi.01699-08 |
0.438 |
|
| 2009 |
Kalinski P, Edington H, Butterfield L, Whiteside T, Bartlett D, Kirkwood J. OR.76. Continuous Intra-lymphatic Infusion of Dendritic Cells as Therapy of Advanced Melanoma Clinical Immunology. 131: S31. DOI: 10.1016/J.Clim.2009.03.524 |
0.358 |
|
| 2008 |
Muthuswamy R, Urban J, Lee JJ, Reinhart TA, Bartlett D, Kalinski P. Ability of mature dendritic cells to interact with regulatory T cells is imprinted during maturation. Cancer Research. 68: 5972-8. PMID 18632653 DOI: 10.1158/0008-5472.Can-07-6818 |
0.559 |
|
| 2008 |
Lee JJ, Foon KA, Mailliard RB, Muthuswamy R, Kalinski P. Type 1-polarized dendritic cells loaded with autologous tumor are a potent immunogen against chronic lymphocytic leukemia. Journal of Leukocyte Biology. 84: 319-25. PMID 18426971 DOI: 10.1189/Jlb.1107737 |
0.56 |
|
| 2008 |
Watchmaker PB, Urban JA, Berk E, Nakamura Y, Mailliard RB, Watkins SC, van Ham SM, Kalinski P. Memory CD8+ T cells protect dendritic cells from CTL killing. Journal of Immunology (Baltimore, Md. : 1950). 180: 3857-65. PMID 18322193 DOI: 10.4049/Jimmunol.180.6.3857 |
0.78 |
|
| 2007 |
Okada H, Lieberman FS, Walter KA, Lunsford LD, Kondziolka DS, Bejjani GK, Hamilton RL, Torres-Trejo A, Kalinski P, Cai Q, Mabold JL, Edington HD, Butterfield LH, Whiteside TL, Potter DM, et al. Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas. Journal of Translational Medicine. 5: 67. PMID 18093335 DOI: 10.1186/1479-5876-5-67 |
0.45 |
|
| 2007 |
Nakamura Y, Watchmaker P, Urban J, Sheridan B, Giermasz A, Nishimura F, Sasaki K, Cumberland R, Muthuswamy R, Mailliard RB, Larregina AT, Falo LD, Gooding W, Storkus WJ, Okada H, ... ... Kalinski P, et al. Helper function of memory CD8+ T cells: heterologous CD8+ T cells support the induction of therapeutic cancer immunity. Cancer Research. 67: 10012-8. PMID 17942935 DOI: 10.1158/0008-5472.Can-07-1735 |
0.536 |
|
| 2007 |
Fan Z, Huang XL, Kalinski P, Young S, Rinaldo CR. Dendritic cell function during chronic hepatitis C virus and human immunodeficiency virus type 1 infection. Clinical and Vaccine Immunology : Cvi. 14: 1127-37. PMID 17634507 DOI: 10.1128/Cvi.00141-07 |
0.411 |
|
| 2007 |
Wesa A, Kalinski P, Kirkwood JM, Tatsumi T, Storkus WJ. Polarized type-1 dendritic cells (DC1) producing high levels of IL-12 family members rescue patient TH1-type antimelanoma CD4+ T cell responses in vitro. Journal of Immunotherapy (Hagerstown, Md. : 1997). 30: 75-82. PMID 17198085 DOI: 10.1097/01.Cji.0000211316.15278.6E |
0.574 |
|
| 2007 |
Ito N, DeMarco RA, Mailliard RB, Han J, Rabinowich H, Kalinski P, Stolz DB, Zeh HJ, Lotze MT. Cytolytic cells induce HMGB1 release from melanoma cell lines. Journal of Leukocyte Biology. 81: 75-83. PMID 16968820 DOI: 10.1189/Jlb.0306169 |
0.456 |
|
| 2007 |
Lee J, Mailliard R, Muthuswamy R, Foon KA, Kalinski P. Generation of alpha-Type-1 Polarized Dendritic Cells as a Potent Immunogen in Patients with Chronic Lymphocytic Leukemia. Blood. 110: 2059-2059. DOI: 10.1182/Blood.V110.11.2059.2059 |
0.553 |
|
| 2007 |
Kalinski P. Treg cells, cancer vaccines: timing is everything Blood. 110: 3090-3091. DOI: 10.1182/Blood-2007-07-102921 |
0.379 |
|
| 2006 |
Kalinski P, Nakamura Y, Watchmaker P, Giermasz A, Muthuswamy R, Mailliard RB. Helper roles of NK and CD8+ T cells in the induction of tumor immunity. Polarized dendritic cells as cancer vaccines. Immunologic Research. 36: 137-46. PMID 17337774 DOI: 10.1385/Ir:36:1:137 |
0.602 |
|
| 2005 |
Mailliard RB, Alber SM, Shen H, Watkins SC, Kirkwood JM, Herberman RB, Kalinski P. IL-18-induced CD83+CCR7+ NK helper cells. The Journal of Experimental Medicine. 202: 941-53. PMID 16203865 DOI: 10.1084/Jem.20050128 |
0.507 |
|
| 2005 |
Kalinski P, Mailliard RB, Giermasz A, Zeh HJ, Basse P, Bartlett DL, Kirkwood JM, Lotze MT, Herberman RB. Natural killer-dendritic cell cross-talk in cancer immunotherapy. Expert Opinion On Biological Therapy. 5: 1303-15. PMID 16197336 DOI: 10.1517/14712598.5.10.1303 |
0.582 |
|
| 2005 |
Kalinski P, Moser M. Consensual immunity: success-driven development of T-helper-1 and T-helper-2 responses. Nature Reviews. Immunology. 5: 251-60. PMID 15738955 DOI: 10.1038/Nri1569 |
0.476 |
|
| 2005 |
Kalinski P, Giermasz A, Nakamura Y, Basse P, Storkus WJ, Kirkwood JM, Mailliard RB. Helper role of NK cells during the induction of anticancer responses by dendritic cells. Molecular Immunology. 42: 535-9. PMID 15607810 DOI: 10.1016/J.Molimm.2004.07.038 |
0.56 |
|
| 2005 |
Wesa A, Kalinski P, Kirkwood JM, Storkus WJ. Rescuing Anti-melanoma CD4+ Responses With Type-1 Polarized Dendritic Cells: Essential Roles of Extended IL-12 Family Members Journal of Immunotherapy. 28: 661. DOI: 10.1097/01.Cji.0000191105.81066.35 |
0.416 |
|
| 2005 |
Kalinski P, Mailliard RB, Geskin L, Giermasz A, Nakamura Y, Storkus WJ, Lotze MT, Bartlett DL, Kirkwood JM, Falo LD. Polarized DC1-Based Therapeutic Cancer Vaccines Journal of Immunotherapy. 28: 656. DOI: 10.1097/01.Cji.0000191090.97275.78 |
0.382 |
|
| 2004 |
Mailliard RB, Wankowicz-Kalinska A, Cai Q, Wesa A, Hilkens CM, Kapsenberg ML, Kirkwood JM, Storkus WJ, Kalinski P. alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Research. 64: 5934-7. PMID 15342370 DOI: 10.1158/0008-5472.Can-04-1261 |
0.485 |
|
| 2004 |
Wesa A, Kalinski P, Kirkwood JM, Storkus WJ. Restoration of TH1 CD4+ T Cell Responses to Melanoma Antigens with Type-1 Polarized Dendritic Cells Journal of Immunotherapy. 27: S34. DOI: 10.1097/00002371-200411000-00124 |
0.516 |
|
| 2004 |
Kalinski P, Mailliard R, Giermasz A, Wankowicz A, Cai Q, Wesa A, Falo L, Storkus W, Kirkwood J. Alpha-Type-1-Polarized DC (αDC1): DC-Based Vaccines with Optimized Anti-Cancer Activity Journal of Immunotherapy. 27: S24. DOI: 10.1097/00002371-200411000-00088 |
0.387 |
|
| 2004 |
Giermasz A, Nakamura Y, Björck P, Watchmaker P, Mailliard R, Kalinski P. Type 1 Polarized Dendritic Cells as Superior Therapeutic Vaccines Against Melanoma Journal of Immunotherapy. 27: S22. DOI: 10.1097/00002371-200411000-00082 |
0.388 |
|
| 2003 |
Mailliard RB, Son YI, Redlinger R, Coates PT, Giermasz A, Morel PA, Storkus WJ, Kalinski P. Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper function. Journal of Immunology (Baltimore, Md. : 1950). 171: 2366-73. PMID 12928383 DOI: 10.4049/Jimmunol.171.5.2366 |
0.561 |
|
| 2003 |
O'Connell PJ, Son YI, Giermasz A, Wang Z, Logar AJ, Thomson AW, Kalinski P. Type-1 polarized nature of mouse liver CD8alpha- and CD8alpha+ dendritic cells: tissue-dependent differences offset CD8alpha-related dendritic cell heterogeneity. European Journal of Immunology. 33: 2007-13. PMID 12884867 DOI: 10.1002/Eji.200323379 |
0.493 |
|
| 2003 |
Kalinski P, Lebre MC, Kramer D, De Jong EC, Van Schijndel JW, Kapsenberg ML. Analysis of the CD4+ T cell responses to house dust mite allergoid. Allergy. 58: 648-56. PMID 12823126 DOI: 10.1034/j.1398-9995.2003.00240.x |
0.312 |
|
| 2003 |
Lebre MC, Antons JC, Kalinski P, Schuitemaker JH, van Capel TM, Kapsenberg ML, De Jong EC. Double-stranded RNA-exposed human keratinocytes promote Th1 responses by inducing a Type-1 polarized phenotype in dendritic cells: role of keratinocyte-derived tumor necrosis factor alpha, type I interferons, and interleukin-18. The Journal of Investigative Dermatology. 120: 990-7. PMID 12787126 DOI: 10.1046/J.1523-1747.2003.12245.X |
0.49 |
|
| 2003 |
Kalinski P, Vieira P, Schuitemaker JH, Cai Q, Kapsenberg M. Generation of human type 1- and type 2-polarized dendritic cells from peripheral blood. Methods in Molecular Biology (Clifton, N.J.). 215: 427-36. PMID 12512318 DOI: 10.1385/1-59259-345-3:427 |
0.343 |
|
| 2002 |
Lokshin AE, Kalinski P, Sassi RR, Mailliard RB, Müller-Berghaus J, Storkus WJ, Peng X, Marrangoni AM, Edwards RP, Gorelik E. Differential regulation of maturation and apoptosis of human monocyte-derived dendritic cells mediated by MHC class II. International Immunology. 14: 1027-37. PMID 12202400 DOI: 10.1093/Intimm/Dxf073 |
0.432 |
|
| 2002 |
Son YI, Egawa S, Tatsumi T, Redlinger RE, Kalinski P, Kanto T. A novel bulk-culture method for generating mature dendritic cells from mouse bone marrow cells. Journal of Immunological Methods. 262: 145-57. PMID 11983228 DOI: 10.1016/S0022-1759(02)00013-3 |
0.491 |
|
| 2002 |
Mailliard RB, Egawa S, Cai Q, Kalinska A, Bykovskaya SN, Lotze MT, Kapsenberg ML, Storkus WJ, Kalinski P. Complementary dendritic cell-activating function of CD8+ and CD4+ T cells: helper role of CD8+ T cells in the development of T helper type 1 responses. The Journal of Experimental Medicine. 195: 473-83. PMID 11854360 DOI: 10.1084/Jem.20011662 |
0.52 |
|
| 2002 |
de Jong EC, Vieira PL, Kalinski P, Schuitemaker JH, Tanaka Y, Wierenga EA, Yazdanbakhsh M, Kapsenberg ML. Microbial compounds selectively induce Th1 cell-promoting or Th2 cell-promoting dendritic cells in vitro with diverse th cell-polarizing signals. Journal of Immunology (Baltimore, Md. : 1950). 168: 1704-9. PMID 11823500 DOI: 10.4049/Jimmunol.168.4.1704 |
0.496 |
|
| 2002 |
Smits HH, Hilkens CM, Kalinski P, Kapsenberg ML, Wierenga EA. How to deal with polarized Th2 cells: exploring the Achilles' heel. International Archives of Allergy and Immunology. 126: 102-10. PMID 11729347 DOI: 10.1159/000049500 |
0.479 |
|
| 2001 |
Kanto T, Kalinski P, Hunter OC, Lotze MT, Amoscato AA. Ceramide mediates tumor-induced dendritic cell apoptosis. Journal of Immunology (Baltimore, Md. : 1950). 167: 3773-84. PMID 11564794 DOI: 10.4049/Jimmunol.167.7.3773 |
0.42 |
|
| 2001 |
Kaliński P, Vieira PL, Schuitemaker JH, de Jong EC, Kapsenberg ML. Prostaglandin E(2) is a selective inducer of interleukin-12 p40 (IL-12p40) production and an inhibitor of bioactive IL-12p70 heterodimer. Blood. 97: 3466-9. PMID 11369638 DOI: 10.1182/Blood.V97.11.3466 |
0.364 |
|
| 2001 |
Okada H, Pollack IF, Lieberman F, Lunsford LD, Kondziolka D, Schiff D, Attanucci J, Edington H, Chambers W, Kalinski P, Kinzler D, Whiteside T, Elder E, Potter D. Gene therapy of malignant gliomas: a pilot study of vaccination with irradiated autologous glioma and dendritic cells admixed with IL-4 transduced fibroblasts to elicit an immune response. Human Gene Therapy. 12: 575-95. PMID 11268289 DOI: 10.1089/104303401300042528 |
0.334 |
|
| 2000 |
Kapsenberg ML, Hilkens CM, van Der Pouw Kraan TC, Wierenga EA, Kalinski P. Atopic allergy: a failure of antigen-presenting cells to properly polarize helper T cells? American Journal of Respiratory and Critical Care Medicine. 162: S76-80. PMID 10988156 DOI: 10.1164/Ajrccm.162.Supplement_2.Ras-4 |
0.505 |
|
| 2000 |
Kaliński P, Smits HH, Schuitemaker JH, Vieira PL, van Eijk M, de Jong EC, Wierenga EA, Kapsenberg ML. IL-4 is a mediator of IL-12p70 induction by human Th2 cells: reversal of polarized Th2 phenotype by dendritic cells. Journal of Immunology (Baltimore, Md. : 1950). 165: 1877-81. PMID 10925267 DOI: 10.4049/Jimmunol.165.4.1877 |
0.439 |
|
| 2000 |
Vieira PL, de Jong EC, Wierenga EA, Kapsenberg ML, Kaliński P. Development of Th1-inducing capacity in myeloid dendritic cells requires environmental instruction. Journal of Immunology (Baltimore, Md. : 1950). 164: 4507-12. PMID 10779751 DOI: 10.4049/Jimmunol.164.9.4507 |
0.492 |
|
| 2000 |
Kaliński P, Hilkens CM, Wierenga EA, Kapsenberg ML. T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. Immunology Today. 20: 561-7. PMID 10562707 DOI: 10.1016/S0167-5699(99)01547-9 |
0.54 |
|
| 1999 |
de Jong EC, Vieira PL, Kalinski P, Kapsenberg ML. Corticosteroids inhibit the production of inflammatory mediators in immature monocyte-derived DC and induce the development of tolerogenic DC3. Journal of Leukocyte Biology. 66: 201-4. PMID 10449154 DOI: 10.1002/Jlb.66.2.201 |
0.538 |
|
| 1999 |
Kapsenberg ML, Kalinski P. The concept of type 1 and type 2 antigen-presenting cells. Immunology Letters. 69: 5-6. PMID 10436874 DOI: 10.1016/S0165-2478(99)00096-6 |
0.358 |
|
| 1999 |
Kapsenberg ML, Hilkens CM, Wierenga EA, Kalinski P. The role of antigen-presenting cells in the regulation of allergen-specific T cell responses. Current Opinion in Immunology. 10: 607-13. PMID 9914218 DOI: 10.1016/S0952-7915(98)80077-0 |
0.468 |
|
| 1999 |
Snijders A, Kalinski P, Hilkens CM, Kapsenberg ML. High-level IL-12 production by human dendritic cells requires two signals. International Immunology. 10: 1593-8. PMID 9846688 DOI: 10.1093/Intimm/10.11.1593 |
0.481 |
|
| 1999 |
Kapsenberg ML, Hilkens CMU, Wierenga EA, Kalinski P. The paradigm of type 1 and type 2 antigen-presenting cells. Implications for atopic allergy Clinical & Experimental Allergy. 29: 33-36. DOI: 10.1046/J.1365-2222.1999.00006.X-I2 |
0.515 |
|
| 1997 |
Kaliński P, Hilkens CM, Snijders A, Snijdewint FG, Kapsenberg ML. Dendritic cells, obtained from peripheral blood precursors in the presence of PGE2, promote Th2 responses. Advances in Experimental Medicine and Biology. 417: 363-7. PMID 9286387 DOI: 10.1007/978-1-4757-9966-8_59 |
0.461 |
|
| 1997 |
Hilkens CM, Kalinski P, de Boer M, Kapsenberg ML. Human Dendritic Cells Require Exogenous Interleukin-12–Inducing Factors to Direct the Development of Naive T-Helper Cells Toward the Th1 Phenotype Blood. 90: 1920-1926. DOI: 10.1182/Blood.V90.5.1920 |
0.503 |
|
| 1997 |
Kaliński P, Hilkens C, Schuitemaker J, de Jong E, Kapsenberg M. Th1- versus Th2- inducing CD1a+CD83+ dendritic cells, which mature in the absence or in the presence of PGE2 Immunology Letters. 56: 354. DOI: 10.1016/S0165-2478(97)86431-0 |
0.447 |
|
| 1997 |
Hilkens C, Kalinski P, de Boer M, Kapsenberg M. Development of human naive T helper cells towards the Th1 phenotype requires activation of dendritic cells by exogenous factors Immunology Letters. 56: 273. DOI: 10.1016/S0165-2478(97)86093-2 |
0.47 |
|
| Show low-probability matches. |